Immunohistochemical Characterization of DU-PAN-2 Expression in Endometrial Adenocarcinomas Associated With CA19-9 Expression

Immunohistochemical Study of Type-1 Blood Antigen Expressions in Thyroid Tumors: The Significance for Papillary Carcinomas

“…Evidence of frequent expression of CA19 -9 in papillary carcinomas of the thyroid has been provided by previous investigations (14,17). Several immunohistochemical studies, including our own in normal endometrium (15) and endometrial adenocarcinoma (16), have shown the expression of these antigens in normal mucosa as well as in adenocarcinomas of other sites (10 -16). However, normal thyroid tissue was invariably negative for these antigens.…”

“…Indeed, papillary carcinomas of the thyroid occur predominantly in females during their reproductive years (20,21). Our recent studies have indicated that hormonal factors would influence the expressions of DU-PAN-2 and CA19 -9 in normal endometrium but not those in endometrial carcinomas (15,16). We thus examined whether the alteration of the female sex hormone environment would give rise to significant changes of expressions of DU-PAN-2, CA19 -9, Le a , and Le b in thyroid tumors.…”

“…It is assumed that these antigen expressions in the normal endometrium would be closely regulated under the female sex hormone environment (15). Subsequently, we have demonstrated that DU-PAN-2 is expressed more frequently than CA19 -9 in endometrial adenocarcinomas but with no correlation to menopausal status of the patients (16).…”

Clinicopathological Analysis of DU-PAN-2 as a Tumor Marker for Endometrial Adenocarcinoma in Comparison with CA19-9.

“…As a result, we reported that DU-PAN-2 and CA19-9 expressions in the normal endometrium were strongly dependent on hormonal regulation during the menstrual cycle, with the highest expression in the secretory phase [4]. We then demonstrated that DU-PAN-2 expression was more frequent than that of CA19-9 in EMACs of various grades, with no correlation to menopausal status [10]. Based on these results, we designed the current study with the aim of investigating whether DU-PAN-2 might be clinically useful in diagnosing and monitoring EMACs.…”

“…The primary antibodies used were as follows; clone DU-PAN-2, diluted at 1:50 (Kyowa Medex, Mishima, Japan); clone 1116-NS-19-9, diluted at 1:50 (Fujirebio Diagnostics, Malvern, PA) [4,10]. As positive controls, a pancreatic carcinoma with a high serum DU-PAN-2 value and one with a high serum CA19-9 value were used.…”